Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial

被引：76

作者：

Smits, Maarten L. J. ^{[1
]}

Nijsen, Johannes F. W. ^{[1
]}

van den Bosch, Maurice A. A. J. ^{[1
]}

Lam, Marnix G. E. H. ^{[1
]}

Vente, Maarten A. D. ^{[1
]}

Huijbregts, Julia E. ^{[1
]}

van het Schip, Alfred D. ^{[1
]}

Elschot, Mattijs ^{[1
]}

Bult, Wouter ^{[1
]}

de Jong, Hugo W. A. M. ^{[1
]}

Meulenhoff, Pieter C. W. ^{[2
]}

Zonnenberg, Bernard A. ^{[1
]}

机构：

[1] Univ Med Ctr Utrecht, Dept Radiol & Nucl Med, NL-3584 CX Utrecht, Netherlands

[2] Univ Med Ctr Utrecht, Dept Clin Pharm, NL-3584 CX Utrecht, Netherlands

来源：

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | 2010年 / 29卷

关键词：

POLY(L-LACTIC ACID) MICROSPHERES; COLORECTAL-CANCER; Y-90; MICROSPHERES; MALIGNANCIES; THERAPY; BRACHYTHERAPY; TUMORS;

D O I：

10.1186/1756-9966-29-70

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Intra-arterial radioembolization with yttrium-90 microspheres (Y-90-RE) is an increasingly used therapy for patients with unresectable liver malignancies. Over the last decade, radioactive holmium-166 poly(L-lactic acid) microspheres (Ho-166-PLLA-MS) have been developed as a possible alternative to Y-90-RE. Next to high-energy beta-radiation, Ho-166 also emits gamma-radiation, which allows for imaging by gamma scintigraphy. In addition, Ho is a highly paramagnetic element and can therefore be visualized by MRI. These imaging modalities are useful for assessment of the biodistribution, and allow dosimetry through quantitative analysis of the scintigraphic and MR images. Previous studies have demonstrated the safety of Ho-166-PLLA-MS radioembolization (Ho-166-RE) in animals. The aim of this phase I trial is to assess the safety and toxicity profile of Ho-166-RE in patients with liver metastases. Methods: The HEPAR study (Holmium Embolization Particles for Arterial Radiotherapy) is a non-randomized, open label, safety study. We aim to include 15 to 24 patients with liver metastases of any origin, who have chemotherapy-refractory disease and who are not amenable to surgical resection. Prior to treatment, in addition to the standard technetium-99m labelled macroaggregated albumin (Tc-99m-MAA) dose, a low radioactive safety dose of 60-mg Ho-166-PLLA-MS will be administered. Patients are treated in 4 cohorts of 3-6 patients, according to a standard dose escalation protocol (20 Gy, 40 Gy, 60 Gy, and 80 Gy, respectively). The primary objective will be to establish the maximum tolerated radiation dose of Ho-166-PLLA-MS. Secondary objectives are to assess tumour response, biodistribution, performance status, quality of life, and to compare the Ho-166-PLLA-MS safety dose and the Tc-99m-MAA dose distributions with respect to the ability to accurately predict microsphere distribution. Discussion: This will be the first clinical study on Ho-166-RE. Based on preclinical studies, it is expected that Ho-166-RE has a safety and toxicity profile comparable to that of Y-90-RE. The biochemical and radionuclide characteristics of Ho-166-PLLA-MS that enable accurate dosimetry calculations and biodistribution assessment may however improve the overall safety of the procedure.

引用

页数：11

共 38 条

[1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].

AARONSON, NK ;

AHMEDZAI, S ;

BERGMAN, B ;

BULLINGER, M ;

CULL, A ;

DUEZ, NJ ;

FILIBERTI, A ;

FLECHTNER, H ;

FLEISHMAN, SB ;

DEHAES, JCJM ;

KAASA, S ;

KLEE, M ;

OSOBA, D ;

RAZAVI, D ;

ROFE, PB ;

SCHRAUB, S ;

SNEEUW, K ;

SULLIVAN, M ;

TAKEDA, F .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376

[2] NATURAL-HISTORY OF PATIENTS WITH UNTREATED LIVER METASTASES FROM COLORECTAL-CANCER [J].

BENGTSSON, G ;

CARLSSON, G ;

HAFSTROM, L ;

JONSSON, P .

AMERICAN JOURNAL OF SURGERY, 1981, 141 (05) :586-589

[3] Determinants of unresectability and outcome of patients with occult colorectal hepatic metastases [J].

Bennett, JJ ;

Cao, DC ;

Posner, MC .

JOURNAL OF SURGICAL ONCOLOGY, 2005, 92 (01) :64-69

[4]

Bolch WE, 1999, J NUCL MED, V40, p11S

[5]

Bult W, 2009, Q J NUCL MED MOL IM, V53, P325

[6] Management of hepatic metastases [J].

Choti, MA ;

Bulkley, GB .

LIVER TRANSPLANTATION AND SURGERY, 1999, 5 (01) :65-80

[7] Hybrid scatter correction applied to quantitative holmium-166 SPECT [J].

de Wit, Tim C. ;

Xiao, Jianbin ;

Nijsen, J. Frank W. ;

Schip, Fred D. van het ;

Staelens, Steven G. ;

van Rijk, Peter P. ;

Beekman, Freek J. .

PHYSICS IN MEDICINE AND BIOLOGY, 2006, 51 (19) :4773-4787

[8] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[9]

Goin JE, 2004, World J Nucl Med, V3, P49

[10] Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis [J].

Golfinopoulos, Vassilis ;

Salanti, Georgia ;

Pavlidis, Nicholas ;

Ioannidis, John P. A. .

LANCET ONCOLOGY, 2007, 8 (10) :898-911

← 1 2 3 4 →